At an event hosted in Washington DC yesterday, a tripartite US-Ireland R&D partnership was announced by Science Foundation Ireland.
The “Centre-to-Centre” collaboration project is titled ‘Partnership in continuous manufacturing for nano-based drug products.’
It will link together three of the world’s significant research centres in pharmaceutical manufacturing including the Science Foundation Ireland Research Centre, Synthesis and Solid State Pharmaceutical Centre (SSPC) located at University of Limerick, the Center for Structured Organic Particulate Systems (C-SOPS) at Purdue University and Rutgers University, USA and the Centre for Pharmaceutical Sciences (CPS) at Queens University Belfast, Northern Ireland.
The project will be funded by Science Foundation Ireland in Ireland, the National Science Foundation (NSF) in the US, and the Department of Employment and Learning Northern Ireland (DEL/NI) in the UK.
The aim of the collaboration is to establish and deliver new end-to-end continuous manufacturing capabilities for poorly soluble micron and nano-sized drugs. It hopes to transform the global supply chain for medicines by developing techniques capable of making nano-particulate active pharmaceutical ingredients and retaining their desirable nano properties throughout the entire manufacturing process.
This will increase the number of available medicines, improve production efficiency and minimize the quantities of dangerous chemicals in production.
Director General at Science Foundation Ireland and Chief Scientific Adviser to the Government of Ireland, Professor Mark Ferguson said, "I welcome the partnership between these three research Centres and encourage the growth and collaboration of scientific links between our countries. These partnerships are not only advancing scientific research but are also delivering important economic, societal and reputational benefits for Ireland."
Source: www.businessworld.ie
